A recent editorial in the Drug and Therapeutics Bulletin questions whether adding ezetimibe to simvastatin▼ is a cost-effective or outcome-based intervention, and whether the increasing monies being spent on ezetimibe (more than £70million in 2009) is a rational use of NHS resources.
via npci.org.uk
No comments:
Post a Comment